Episode of The BioHub Podcast featuring our Chief Operating Officer Martijn Negen.

In Q4 2025, VarmX signed a strategic collaboration with CSL worth up to $2.1 billion in milestones. This will fully fund a global phase3 trial & pre-launch readiness for their lead asset VMX-C001 – a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs.

Martijn shares insight on how the deal came about, what it could mean for patients and VarmX in future, and why CSL are the right partner to develop & deliver VMX-C001 globally.